1. Scrip
  2. >>R&D

Up, Up And Away: A Comparison Of Industry R&D Spend Now Versus 10 Years Ago

 
• By Jessica Merrill

Average R&D spending by the top 25 biopharma companies increased as a percent of sales from 14.4% in 2010 to 17% in 2020, according to an EY report.

price tag
R&D spending has increased over 10 years • Source: Alamy

The top biopharma companies are spending more on R&D than they did 10 years ago as a percentage of sales but even with investment, R&D productivity will not offset a looming patent cliff that begins in 2023 when AbbVie Inc. will lose US exclusivity for Humira (adalimumab) and peaks in the 2025/2026 time period, according to a report from the consulting firm EY.

Spending on R&D as a percentage of sales by the top 25 biopharma companies increased from an average of 14.4% in 2010 to an average of 17% in 2020 and 16

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from R&D

More from Scrip

Quick Listen: Scrip’s Five Must-Know Things

 
• By Ian Haydock

In this week's episode: Trump’s executive order more rhetoric than action; industry grapples with Trump pricing plan; Hengrui set for this year’s biggest IPO; Sanofi’s exec’s advice to biotechs; and biotech deal return on investment falls.

A Short History Of MASH Deals, Culminating In GSK/Boston Pharma

 
• By Joseph Haas

Both high-profile failures and small investments that are yielding success so far characterize the dealmaking in MASH over the past 15 years or so.

BioMarin’s $270m Inozyme Buy Fits Right Into Enzyme Therapy Business

 
• By Mandy Jackson

BioMarin’s chief business officer James Sabry told Scrip that Inozyme’s enzyme replacement therapy INZ-701 aligns with the company’s existing portfolio and its areas of dealmaking focus.